Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 9 PDSB PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
May 9 GRTS Gritstone bio GAAP EPS of -$0.34 misses by $0.02, revenue of $1.74M misses by $1.11M
May 9 GNLX Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 9 GRTS Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 9 CGON CG Oncology, Inc. reports Q1 results
May 9 CGON CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 9 PDSB PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
May 8 GRTS Gritstone bio Q1 2024 Earnings Preview
May 7 GOVX GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 7 PDSB PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
May 6 CGON CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 6 SABS SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 5 GNLX Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders
May 3 CGON CG Oncology reports data from Phase 3 bladder cancer study
May 3 CGON CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
May 3 CGON Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 3 CGON Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
May 3 PDSB PDS Biotechnology Announces Details of Virtual KOL Event
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags